Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes
| Autor: | C, Kragelund, C E, Thomsen, A, Bardow, A M, Pedersen, B, Nauntofte, J, Reibel, L A, Torpet |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Age Factors Genetic Variation Middle Aged Gene Expression Regulation Enzymologic Cross-Sectional Studies Sex Factors Cytochrome P-450 Enzyme System Drug Therapy Pharmaceutical Preparations Case-Control Studies Polypharmacy Cytochrome P-450 Enzyme Inhibitors Humans Disease Female Aged Lichen Planus Oral |
| Zdroj: | Oral diseases. 9(4) |
| ISSN: | 1354-523X |
| Popis: | To study if patients with oral lichen planus (OLP) had a medication profile different from that of a control group without oral mucosal lesions. It was hypothesized that OLP lesions might result from poor drug metabolism (PM) because of genetic variation of the major cytochrome P450-enzymes (CYPs with a PM-risk).Dental records of 172 OLP patients were reviewed in this cross-sectional study and 152 sex- and age-matched subjects served as controls. The measures for the drug profiles were medicine type (ATC-code), mono- and polypharmacy, CYP-enzyme metabolism pattern, and medicine with a potential to induce lichenoid drug eruptions.Fifty per cent of the OLP patients consumed daily medications as compared with 59% of the controls. The OLP patients more frequently consumed medicines metabolized by CYPs with a PM-risk (P = 0.03). Furthermore, they consumed more medicine with an inhibitory effect on one or more CYPs than the controls (P = 0.01).Confounders like sex, age, systemic diseases, drug distribution into the therapeutic classes, and polypharmacy were similar in the two groups; but the OLP patients consumed more drugs metabolized by CYPs with a PM-risk. The results argue for further investigation of associations between OLP, medication intake and the CYP-enzyme metabolic pathways. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text